Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial

Autor:	Stefan Martinoff, Stephan G. Nekolla, Adnan Kastrati, Melchior Seyfarth, Josef Dirschinger, Jodi Neverve, Julinda Mehilli, Rudolf Blasini, Ullrich Schricke, Jürgen Pache, Albert Schömig, Franz-Josef Neumann, Markus Schwaiger
Rok vydání:	2002
Předmět:	Male medicine.medical_specialty Abciximab medicine.medical_treatment Myocardial Infarction law.invention Immunoglobulin Fab Fragments Randomized controlled trial law Angioplasty Internal medicine Fibrinolysis medicine Clinical endpoint Humans Myocardial infarction Radionuclide Imaging Aged Salvage Therapy business.industry Antibodies Monoclonal Stent General Medicine Middle Aged medicine.disease Treatment Outcome Relative risk Cardiology Female Stents business medicine.drug
Zdroj:	The Lancet. 359:920-925
ISSN:	0140-6736
DOI:	10.1016/s0140-6736(02)08022-4
Popis:	Summary Background Patients with acute myocardial infarction might benefit from the addition of glycoprotein IIb/IIIa inhibitors to fibrinolytic or mechanical reperfusion strategies. We compared two strategies, stenting and fibrinolysis, both combined with abciximab, in terms of their ability to salvage myocardium in patients with acute myocardial infarction. Methods We enrolled 162 patients with acute myocardial infarction within 12 h of onset of symptoms, assigning 81 stenting plus abciximab and 81 alteplase plus abciximab. Technetium-99m sestamibi scintigraphy was done at admission and after a median of 11 days to calculate initial perfusion defect, final infarct size, and degree of myocardial salvage. The primary endpoint was the salvage index (the ratio of the degree of myocardial salvage to the initial perfusion defect). Major adverse clinical events within 6 months from randomisation were also compared between the two treatments. Findings Paired scintigraphic measurements were available for 70 patients in the stent group and 71 in the alteplase group. Stenting was associated with greater myocardial salvage than alteplase (median 13.6% [IQR 5.9-23.9] vs 8.0% [2.5-16.0] of the left ventricle; p=0.007). Salvage index was greater in the stent group than in the alteplase group (median 0.60 [0.37-0.82] vs 0.41 [0.13-0.58]; p=0.001). The 6-month mortality rate was 5% (four deaths) in the stent group and 9% (seven deaths) in the alteplase group (relative risk 0.56 [95% CI 0.17-1.88]; p=0.35). Interpretation In patients with acute myocardial infarction, a reperfusion strategy based on stenting with abciximab produced more myocardial salvage than the combination of fibrinolysis plus abciximab. Larger studies are needed to assess whether these effects translate into clinical benefit.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e77988d38913785ed778e9aceff15c1 https://doi.org/10.1016/s0140-6736(02)08022-4 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.